Overview

• The U.S. Food and Drug Administration (FDA) has approved Aurlumyn, the first-ever treatment for severe frostbite in adults, aimed at reducing the risk of finger or toe amputation.
• Aurlumyn, also known as iloprost, is an injectable vasodilator that opens blood vessels and prevents blood clots, initially approved in 2004 for pulmonary arterial hypertension.
• In a controlled trial, Aurlumyn demonstrated a significant reduction in the need for amputation among severe frostbite patients compared to other treatments.
• Common side effects of Aurlumyn include headache, flushing, heart palpitations, fast heart rate, nausea, vomiting, dizziness, and hypotension.
• Experts emphasize the importance of frostbite prevention through proper clothing, equipment, and training for cold-weather activities.